Brain natriuretic peptide gene polymorphism in patients with congestive heart failure

Cover Page

Cite item

Full Text

Abstract

Aim. To study the influence of brain natriuretic peptide gene polymorphism (polymorphic locus Т-381С) on brain natriuretic peptide serum level and congestive heart failure onset risk and clinical features in patients with coronary heart disease. Methods. 412 patients with congestive heart failure were examined. Genotyping was performed by polymerase chain reaction. Brain natriuretic peptide N-terminal fragment level was assessed by ELISA. The control group included 211 healthy controls with no signs of cardiovascular pathology on examination. Results. In healthy people with C/C genotype the level of brain natriuretic peptide N-terminal fragment was significantly higher in comparison with people carrying T/T genotype. It was found that the T allele and T/T genotype of the T-381C natriuretic peptide gene polymorphic locus was associated with high risk, severity and unfavorable clinical course of congestive heart failure in patients with coronary heart disease. At the same time, the C allele and C/C genotype emerged as a protective factor regarding the risk, severity and clinical course of the disease. Conclusion. T/T genotype carriers of the of the T-381C natriuretic peptide gene polymorphic locus are a special subgroup associated with high risk of congestive heart failure onset and unfavorable clinical course. Therefore these patients with coronary heart disease should be considered as a group requiring an out-patient control and preventive measures targeted on congestive heart failure and premature mortality prevention.

About the authors

E N Berezikova

Novosibirsk State Medical University, Novosibirsk, Russia

Email: berezikova@ngs.ru

S D Mayanskaya

Kazan State Medical University, Kazan, Russia

L A Garaeva

Kazan State Medical University, Kazan, Russia

S N Shilov

Novosibirsk State Medical University, Novosibirsk, Russia

A V Efremov

Novosibirsk State Medical University, Novosibirsk, Russia

A T Teplyakov

Scientific and Research Institute of Cardiology, Tomsk, Russia

I D Safronov

Novosibirsk State Medical University, Novosibirsk, Russia

M G Pustovetova

Novosibirsk State Medical University, Novosibirsk, Russia

E N Samsonova

Novosibirsk State Medical University, Novosibirsk, Russia

Y Y Torim

Scientific and Research Institute of Cardiology, Tomsk, Russia

References

  1. Баранов В.С., Баранова Е.В., Иващенко Т.Э., Асеев М.В. Геном человека и гены «предрасположенности» (введение в предиктивную медицину). - СПб.: Интермедика, 2000. - 271 с.
  2. Елисеев О.М. Натрийуретические пептиды. Эволюция знаний // Тер. архив. - 2003. - №9. - С. 40-45.
  3. Хирманов В. Натрийуретические пептиды: перспективы использования в диагностике и лечении сердечной недостаточности // Врач. - 2003. - №7. - С. 37-38.
  4. Azzazy H.M., Christenson R.H. B-type natriuretic peptide: physiologic role and assay characteristics // Heart Fail. Rev. - 2003. - N 8. - Р. 315-320.
  5. Cambien F., Tiret L. Genetics of cardiovascular diseases // Circulation. - 2007. - Vol. 116. - P. 1714-1724.
  6. Denus S., Pharand C., Williamson D. Brain natriuretic peptide in the management of heart failure // Chest. - 2004. - Vol. 125. - P. 652-668.
  7. Furumoto T., Fujii S., Mikami X. et al. Increased plasma concentrations of N-terminal pro-brain natriuretic peptide reflect the presence of mildly reduced left ventricular diastolic function in hypertension // Coron. Artery. Dis. - 2006. - Vol. 17, N 1. - P. 45-50.
  8. Gardner R.S., Ozalp F., Murday A.J. et al. N-terminal pro-brain natriuretic peptide. A new gold standard in predicting mortality in patients with advanced heart failure // Eur. Heart. J. - 2003. - Vol. 24, N 19. - P. 1735-1743.
  9. Hall C. Essential biochemistry and physiology of (NT-pro) BNP // Eur. J. of Heart Fail. - 2004. - Vol. 6. - P. 257-260.
  10. Jernberg T., James S., Lindahl B. et al. NT-proBNP in unstable coronary artery disease - experiences from the FAST, CUSTO IV and FRISC II trials // Eur. J. Heart Fail. - 2004. - Vol. 6. - P. 319-325.
  11. Levin E., Gardner D., Samson W. Natriuretic peptides // N. Engl. J. Med. - 1998. - Vol. 339. - P. 321-328.
  12. Schwartz K. On the pulse of genetic cardiology // Nat. Genet. - 1994. - Vol. 8. - P. 110-111.
  13. Wang T., Larson M., Levy D. et al. Plasma natriuretic peptide levels and the risk of cardiovascular events and death // N. Engl. J. Med. - 2004. - Vol. 350. - P. 655-663.
  14. Woodard G.E., Rosado J.A. Natriuretic peptides in vascular physiology and pathology // Int. Rev. Cell. Mol. Biol. - 2008. - Vol. 268. - P. 59-93.

© 2013 Berezikova E.N., Mayanskaya S.D., Garaeva L.A., Shilov S.N., Efremov A.V., Teplyakov A.T., Safronov I.D., Pustovetova M.G., Samsonova E.N., Torim Y.Y.

Creative Commons License

This work is licensed
under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.




This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies